COR logo

Cencora Inc. (COR)

$339.09

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on COR

Market cap

$64.71B

EPS

13.47

P/E ratio

24

Price to sales

0.19

Dividend yield

0.779%

Beta

0.582965

Price on COR

Previous close

$341.25

Today's open

$344.31

Day's range

$337.86 - $348.57

52 week range

$244.82 - $377.54

Profile about COR

CEO

Robert P. Mauch

Employees

51000

Headquarters

Conshohocken, PA

Exchange

New York Stock Exchange

Shares outstanding

190827165

Issue type

Common Stock

COR industries and sectors

Healthcare

Medical Distributors

News on COR

Dividend Champion, Contender, And Challenger Highlights: Week Of November 22

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

news source

Seeking Alpha • Nov 20, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Trustmark Corporation (Nasdaq – TRMK), Maplebear Inc. (Nasdaq – CART), Investcorp Credit Management BDC, Inc. (Nasdaq – ICMB), American Oncology Network, Inc. (OTCQX – AONC)

BALA CYNWYD, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Nov 19, 2026

news preview

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Cencora's COR fourth-quarter results highlighted the company's strategic shift toward specialty pharmaceuticals, supported by acquisitions, expanding provider relationships and investments in specialty logistics. Its pharmaceutical distribution business continues to provide scale, while the new reporting structure offers greater visibility into the growth potential of specialty operations.

news source

Zacks Investment Research • Nov 18, 2026

news preview

Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November

I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an above-100% payout ratio and likely will increase its annual dividend just one cent. Motorola Solutions (MSI) should deliver a 10%+ increase, while Marzetti (MZTI) is poised to extend its 63-year streak with a roughly 5% boost.

news source

Seeking Alpha • Nov 16, 2026

news preview

US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus

The US antitrust regulator filed a lawsuit on Friday in a New York federal court to ​block Cencora's $3.5 billion sale of its MWI ‌Animal Health unit to veterinary supplier Covetrus, arguing the deal would raise costs for clinics and pet ​owners.

news source

Reuters • Nov 13, 2026

news preview

Dividend Announcements: October 31-November 6, 2026 (Part 2 Of 2)

I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. In this second article in two parts, I highlight 17 Dividend Contenders and 2 special dividends this week. Snap-on (SNA) stands out with a 12.7% dividend hike, 17-year streak, 7.68 Quality Score, and top-tier dividend safety.

news source

Seeking Alpha • Nov 9, 2026

news preview

3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility

BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.

news source

Zacks Investment Research • Nov 6, 2026

news preview

What Cencora (COR) Said on Its Q4 Earnings Call

Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distribution business.

news source

MarketBeat • Nov 5, 2026

news preview

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a no.

news source

Business Wire • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cencora Inc.

Open an M1 investment account to buy and sell Cencora Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in COR on M1